Dementia and Neurocognitive Disorders (대한치매학회지)

Korean Dementia Association (대한치매학회)
권호 표지
DOI QR코드

DOI QR Code

Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association

  • Kee Hyung Park (Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Jae-Won Jang (Department of Neurology, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Jeewon Suh (Department of Neurology, National Medical Center) ;
  • SangHak Yi (Department of Neurology, Wonkwang University Hospital, Wonkwang University School of Medicine) ;
  • Jae-Sung Bae (Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University) ;
  • Jae-Sung Lim (Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hyon Lee (Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine) ;
  • Juhee Chin (Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Young Ho Park (Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Yun Jeong Hong (Department of Neurology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Geon Ha Kim (Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine) ;
  • Academic Committee of the Korean Dementia Association (Korean Dementia Association)
  • Received : 2022.01.31
  • Accepted : 2022.02.20
  • Published : 2022.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer's dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD's diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.

Keywords

Acknowledgement

The authors thank all members of the academic committee of Korean Dementia Association: Kee Hyung Park, Kunho Lee, Juhee Chin, Jae-Won Jang, Seong-Ho Koh, Hee-Jin Kim, Geon Ha Kim, So Young Moon, Young Ho Park, Jae-Sung Lim, Jeewon Suh, Yun Jeong Hong, Byung Seok Ye, Hyon Lee, Jae-Sung Bae, Hoon Ryu, Cheil Moon, Yong Jeong, Hui Jin Ryu, Jaeseol Park, and Jiyoung Yeom.

References

  1. Gurdon B, Kaczorowski C. Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. Neurobiol Dis 2021;161:105558.
  2. Kim HR, Lee T, Choi JK, Jeong Y; Alzheimer's Disease Neuroimaging Initiative. Genetic variants beyond amyloid and tau associated with cognitive decline: a cohort study. Neurology 2020;95:e2366-e2377.
  3. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y) 2021;7:e12179.
  4. Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med 2021;385:309-319. https://doi.org/10.1056/NEJMoa2034634
  5. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016;537:50-56. https://doi.org/10.1038/nature19323
  6. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther 2021;13:98.
  7. Haeberlein SB, von Hehn C, Tian Y, Chalkias S, Muralidharan KK, Chen T, et al. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer's disease. San Diego: 12th Clinical Trials on Alzheimer's Disease, 2019;1-25.
  8. Li C, Gotz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov 2017;16:863-883. https://doi.org/10.1038/nrd.2017.155
  9. Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circ Res 2019;124:1025-1044. https://doi.org/10.1161/CIRCRESAHA.118.313260
  10. Jacobson AM, Ryan CM, Braffett BH, Gubitosi-Klug RA, Lorenzi GM, Luchsinger JA, et al. Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. Lancet Diabetes Endocrinol 2021;9:436-445. https://doi.org/10.1016/S2213-8587(21)00086-3
  11. Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ. Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol 2015;14:329-340. https://doi.org/10.1016/S1474-4422(14)70249-2
  12. Xue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev 2019;55:100944.
  13. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64-74. https://doi.org/10.1016/S1474-4422(05)70284-2
  14. Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SL, Mattheus M, et al. HbA1c, insulin resistance, and β-cell function in relation to cognitive function in type 2 diabetes: the CAROLINA cognition substudy. Diabetes Care 2019;42:e1-e3. https://doi.org/10.2337/dc18-0914
  15. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol 2018;14:591-604. https://doi.org/10.1038/s41574-018-0048-7
  16. Duering M, Zieren N, Herve D, Jouvent E, Reyes S, Peters N, et al. Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. Brain 2011;134:2366-2375. https://doi.org/10.1093/brain/awr169
  17. Duering M, Gesierich B, Seiler S, Pirpamer L, Gonik M, Hofer E, et al. Strategic white matter tracts for processing speed deficits in age-related small vessel disease. Neurology 2014;82:1946-1950. https://doi.org/10.1212/WNL.0000000000000475
  18. Duering M, Righart R, Wollenweber FA, Zietemann V, Gesierich B, Dichgans M. Acute infarcts cause focal thinning in remote cortex via degeneration of connecting fiber tracts. Neurology 2015;84:1685-1692. https://doi.org/10.1212/WNL.0000000000001502
  19. Duering M, Schmidt R. Remote changes after ischaemic infarcts: a distant target for therapy? Brain 2017;140:1818-1820. https://doi.org/10.1093/brain/awx135
  20. Tiedt S, Duering M, Barro C, Kaya AG, Boeck J, Bode FJ, et al. Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology 2018;91:e1338-e1347. https://doi.org/10.1212/WNL.0000000000006282
  21. Wollenweber FA, Darr S, Muller C, Duering M, Buerger K, Zietemann V, et al. Prevalence of amyloid positron emission tomographic positivity in poststroke mild cognitive impairment. Stroke 2016;47:2645-2648. https://doi.org/10.1161/STROKEAHA.116.013778
  22. Mok VCT, Lam BYK, Wang Z, Liu W, Au L, Leung EYL, et al. Delayed-onset dementia after stroke or transient ischemic attack. Alzheimers Dement 2016;12:1167-1176. https://doi.org/10.1016/j.jalz.2016.05.007
  23. Zietemann V, Georgakis MK, Dondaine T, Muller C, Mendyk AM, Kopczak A, et al. Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology 2018;91:e1838-e1850. https://doi.org/10.1212/WNL.0000000000006506
  24. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019;93:e1647-e1659. https://doi.org/10.1212/WNL.0000000000008081
  25. Janelidze S, Teunissen CE, Zetterberg H, Allue JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol 2021;78:1375-1382. https://doi.org/10.1001/jamaneurol.2021.3180
  26. Barthelemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med 2020;217:e20200861.
  27. Horie K, Barthelemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease. Brain 2021;144:515-527. https://doi.org/10.1093/brain/awaa373
  28. Regional Committee for Europe 71st Session. Seventy-first Regional Committee for Europe: virtual session, 13-15 September 2021: global actions on epilepsy and other neurological disorders [Internet]. Copenhagen: World Health Organization Regional Office for Europe; 2021 [cited 2022 Jan 29]. Available from: https://apps.who.int/iris/handle/10665/343347.
  29. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet 2017;390:2673-2734. https://doi.org/10.1016/S0140-6736(17)31363-6
  30. National Institute for Health and Care Excellence. Dementia, disability and frailty in later life - midlife approaches to delay or prevent onset [Internet]. London: National Institute for Health and Care Excellence; 2015 [cited 2021 Dec 30]. Available from: https://www.nice.org.uk/guidance/ng16.